Medip Real-Time Qpcr Has the Potential for Noninvasive Prenatal Screening of Fetal Trisomy 21 Publisher



Kazemi M^{1, 2, 3} ; Salehi M^{1, 2, 3} ; Kheirollahi M³ Show Affiliations
Source: International Journal of Molecular and Cellular Medicine Published:2017

Abstract

This study aimed to verify the reliability of the 7 tissue differentially methylated regions used in the methylatedDNA immunoprecipitation (MeDIP) real- time quantitative polymerase chain reaction (real-time qPCR) basedapproach of fetal DNA in maternal blood to diagnosis of fetal trisomy 21. Forty pregnant women with high riskpregnancy who were referred after first or second trimester screening tests, were selected randomly. For eachsample whole DNA extraction (mother and fetus), fragmentation of DNA, immunoprecipitation of methylatedDNA and real- time qPCR using 7 primer pairs was performed. D-value for each sample was calculated usingthe following formula D = -4.908+ 0.254 XEP1+ 0.409 XEP4+ 0.793 XEP5+ 0.324 XEP6+ 0.505 XEP7+ 0.508 XEP9+0.691 XEP12. In all normal cases, D value was negative, while it was positive in all trisomy cases. Therefore, allnormal and trisomy 21 cases were classified correctly which correspond to 100% specificity and 100%sensitivity for this method. The MeDIP real-time qPCR method has provided the opportunity for noninvasiveprenatal diagnosis of fetal trisomy 21 to be potentially employed into the routine practice of diagnosticlaboratories.